Abstract 1572P
Background
The COVID-19 pandemic is a huge health problem in all countries. To know how COVID-19 infection affected GU cancer patients in Spain, an ambispective clinical registry was elaborated to get clinical information about cancer, its treatment, and the evolution of COVID-19 infection.
Methods
From November 2020 to April 2021, 369 patients (pts) with PCR, antigen or antibody documented SARS-CoV2 infection who were diagnosed or/and treated for a GU tumor, were evaluated in 32 Spanish hospitals. Data were collected in a unitary database with information about cancer diagnosis, treatment, COVID-19 symptoms and outcome.
Results
Median age was 68.4 y (range 17-100), 322 pts (87.3%) were male. Tumor origin was kidney in 82 pts (22.7%), urothelial in 110 (29.8%), prostate 198 (40.7%), testis in 17 (4.6%) and other in 5 (1.4%). 216 (58.5%) pts were receiving active treatment at the moment of the infection: 20 neo/adjuvant treatment and 196 metastatic/palliative treatment. 81 pts (22%) were receiving immuno-oncology (IO), 69 (18.7%) chemotherapy (CT), 36 (9.8%) tyrosine kinase inhibitors (TKI), 67 (18.2%) new anti-androgen therapy, and 101 (27.4%) were on steroids. Most frequent symptoms of COVID-19 were: cough in 138 pts (37.4%), with a median duration of 6.6 days; fever 176 (47.7%), median duration 5.76 days; dyspnea 119 (32.2%), asthenia 82 (22.2%), diarrhea 44 (11.9%) and myalgia 36 (9.8%). Laboratory abnormalities were common, 166 pts (45%) had lymphopenia and 137 (37.1%) D-dimer elevation. 153 (41.5%) presented pneumonia and 119 (32.3%) had patchy pulmonary infiltrates. 132 patients had to be hospitalized (35.8%) and 55 (14.9%) died. The presence of radiological findings, hospitalization and mortality were not related to sex or treatment with IO, CT, TKI or corticosteroids. Median age of pts with radiological pneumonia (72 vs 65.8; p<0.0001), patchy infiltrates (71.4 vs 76; p=0.002), admitted to the ICU (75 vs. 67; p<0,0001) and died (76.1 vs 67.77; p<0,0001) was higher.
Conclusions
Mortality secondary to COVID-19 was higher in GU cancer patients than that described in the general population. As described in other settings, age was the most important risk factor for COVID-19 severe outcomes regardless of tumor type or treatment.
Clinical trial identification
NCT04578132.
Editorial acknowledgement
Legal entity responsible for the study
Spanish Oncology GenitoUrinary Group (SOGUG).
Funding
Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen Pharma, Novartis and Pfizer.
Disclosure
M.A. Climent Duran: Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Invited Speaker: IPSEN; Financial Interests, Personal, Advisory Board: IPSEN; Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Personal, Advisory Board: Astellas; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: EUSA; Financial Interests, Personal, Advisory Board: EUSA; Financial Interests, Personal, Invited Speaker: Merck; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Advisory Board: Sanofi; Financial Interests, Personal, Invited Speaker: Astra; Financial Interests, Personal, Advisory Board: Astra. N. Vidal: Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: MSD; Non-Financial Interests, Personal, Other, Travel: BMS; Non-Financial Interests, Personal, Other, Travel: Pfizer; Non-Financial Interests, Personal, Other, Travel: Pierre Fabre. S. Pérez: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Other, Speaker and advisory role: GSK; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Other, Speaker and advisory role: Bayer; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Invited Speaker: Ipsen. G. Anguera: Financial Interests, Personal, Speaker’s Bureau: Bristol-Myers Squibb; Financial Interests, Personal, Speaker’s Bureau: Ipsen; Financial Interests, Personal, Speaker’s Bureau: Janssen; Financial Interests, Personal, Speaker’s Bureau: Novartis. E. Gallardo: Financial Interests, Personal, Other, Advisory role. Speaking role: Sanofi; Financial Interests, Personal, Other, Advisory role. Speaking role: Janssen; Financial Interests, Personal, Other, Advisory role. Speaking role: Astellas; Financial Interests, Personal, Other, Advisory role. Speaking role: Pfizer; Financial Interests, Personal, Other, Advisory role. Speaking role: Bayer; Financial Interests, Personal, Other, Advisory role. Speaking role: Roche; Financial Interests, Personal, Other, Advisory role. Speaking role: Ipsen; Financial Interests, Personal, Other, Advisory role. Speaking role: EISAI; Financial Interests, Personal, Other, Advisory role. Speaking role: EUSA Pharma; Financial Interests, Personal, Other, Advisory role. Speaking role: BMS; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Other, Advisory role. Speaking role. Writing dossier: Merk; Financial Interests, Personal, Other, Advisory role. Speaking role: Daiichi Sankyo; Financial Interests, Personal, Advisory Role: Techdow; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Menarini; Financial Interests, Personal, Invited Speaker: Rovi; Financial Interests, Personal, Invited Speaker: Leo Pharma; Financial Interests, Personal, Other, Writing review: Novartis; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim; Financial Interests, Institutional, Other, Clinical trials: Astellas & Medivation; Financial Interests, Institutional, Other, Clinical trials: Ipsen; Financial Interests, Institutional, Other, Clinical trials: Janssen; Financial Interests, Institutional, Other, Clinical trials: Pfizer; Financial Interests, Institutional, Other, Clinical trials: Lilly; Financial Interests, Institutional, Other, Clinical trials: Pfizer-Merk; Financial Interests, Institutional, Other, Clinical trials: MSD; Financial Interests, Institutional, Other, Clinical trials: BMS; Financial Interests, Institutional, Other, Clinical trials: Bayer; Financial Interests, Institutional, Other, Clinical trials: Daiichi Sankyo; Financial Interests, Institutional, Other, Clinical trials: Roche; Financial Interests, Institutional, Other, Clinical trials: AstraZeneca; Financial Interests, Institutional, Other, Clinical trials: Novartis; Financial Interests, Institutional, Other, Clinical trials: Seattle Genetics; Financial Interests, Institutional, Other, Clinical trials: Incyte; Financial Interests, Institutional, Other, Clinical trials: Aveo; Financial Interests, Institutional, Other, Clinical trials: Exelixis; Financial Interests, Institutional, Other, Clinical trials: Immunicum; Financial Interests, Institutional, Other, Clinical trials: Mediolanum; Financial Interests, Institutional, Other, Clinical trials: Clovis; Non-Financial Interests, Personal, Member, Vice-president of SOGUG: SOGUG. A. Martín: Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Advisory Board: Sanofi; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: EUSA Pharma; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Principal Investigator: Aveo; Financial Interests, Personal, Principal Investigator: Pfizer; Financial Interests, Institutional, Other, Clinical trial: Aveo; Financial Interests, Institutional, Other, Clinical trial: Pfizer; Non-Financial Interests, Personal, Invited Speaker: SEOM; Non-Financial Interests, Personal, Invited Speaker: SOGUG; Non-Financial Interests, Personal, Invited Speaker: GEICO; Non-Financial Interests, Personal, Invited Speaker: Grupo Centro de Tumores Genitourinarios; Other, Personal, Other, Travel expenses: Pfizer; Other, Personal, Other, Travel expenses: Roche; Other, Personal, Other, Travel expenses: PharmaMar. A. Rodriguez-Vida: Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: Roche; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: MSD; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: Pfizer; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: BMS; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: Astellas; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: Janssen; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: Bayer; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: Clovis; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: AstraZeneca; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: Sanofi; Financial Interests, Personal, Project Lead: Takeda; Financial Interests, Personal, Project Lead: Pfizer; Financial Interests, Personal, Project Lead: Merk. E. Almagro Casado: Financial Interests, Personal, Speaker’s Bureau: PharmaMar; Non-Financial Interests, Personal, Principal Investigator, Principal investigator of several clinical trials: Sponsors. M. Martinez Kareaga: Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: MSD; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: Bristol-Myers Squibb; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: Roche. O. Fernandez Calvo: Financial Interests, Personal, Invited Speaker: Bristol-Myers; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Invited Speaker: EUSA Pharma; Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Pierre Fabre; Financial Interests, Personal, Invited Speaker: Ipsen; Financial Interests, Personal, Advisory Role: Astellas; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Advisory Role: Bristol-Myers; Financial Interests, Personal, Advisory Role: EUSA Pharma; Financial Interests, Personal, Advisory Role: Sanofi; Non-Financial Interests, Personal, Member of the Board of Directors: SOGUG. J.C. Villa Guzmán: Financial Interests, Personal, Other, Educational sessions: Pfizer; Financial Interests, Personal, Other, Educational sessions: AstraZeneca; Financial Interests, Personal, Other, Educational sessions: Roche; Financial Interests, Personal, Other, Educational sessions: Novartis; Financial Interests, Personal, Other, Educational sessions: Sanofi; Financial Interests, Personal, Other, Educational sessions: Bristol; Financial Interests, Personal, Other, Educational sessions: MSD. S. Vazquez: Financial Interests, Personal, Advisory Role: Sanofi/Aventis; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Astellas Pharma; Financial Interests, Personal, Advisory Role: Janssen; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Advisory Role: Bayer; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Eisai; Financial Interests, Personal, Advisory Role: Pierre Fabre; Financial Interests, Personal, Advisory Role: EUSA Pharma; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Other, Travel and accommodation expenses: Astellas Pharma; Financial Interests, Personal, Other, Travel and accommodation expenses: Pfizer; Financial Interests, Personal, Other, Travel and accommodation expenses: Janssen; Financial Interests, Personal, Other, Travel and accommodation expenses: Sanofi; Financial Interests, Personal, Other, Travel and accommodation expenses: BMS; Financial Interests, Personal, Other, Travel and accommodation expenses: MSD; Financial Interests, Personal, Other, Travel and accommodation expenses: Roche; Financial Interests, Personal, Other, Travel and accommodation expenses: Ipsen. A. Gonzalez del Alba: Financial Interests, Personal, Advisory Role: Sanofi/Aventis; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Astellas Pharma; Financial Interests, Personal, Advisory Role: Janssen; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Advisory Role: Bayer; Financial Interests, Personal, Advisory Role: Bristol-Myers-Squibb; Financial Interests, Personal, Advisory Role: Eisai; Financial Interests, Personal, Advisory Role: Pierre Fabre; Financial Interests, Personal, Advisory Role: EUSA Pharma; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Other, Traver and accommodation expenses: Astellas Pharma; Financial Interests, Personal, Other, Traver and accommodation expenses: Pfizer; Financial Interests, Personal, Other, Traver and accommodation expenses: Janssen; Financial Interests, Personal, Other, Traver and accommodation expenses: Sanofi; Financial Interests, Personal, Other, Traver and accommodation expenses: Bristol-Myers Squibb; Financial Interests, Personal, Other, Traver and accommodation expenses: MSD; Financial Interests, Personal, Other, Traver and accommodation expenses: Roche; Financial Interests, Personal, Other, Traver and accommodation expenses: Ipsen. J. Puente: Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Personal, Advisory Board: Astellas; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker: Bayer; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Personal, Advisory Board: Ipsen; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Invited Speaker: Merk; Financial Interests, Personal, Advisory Board: Merk; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Advisory Board: Roche; Non-Financial Interests, Institutional, Research Grant: Astellas; Non-Financial Interests, Institutional, Research Grant: Roche. All other authors have declared no conflicts of interest.